https://www.selleckchem.com/pr....oducts/oxalacetic-ac
The objective response rate was 24% with a CBR of 72%; 43% of patients with pancreatic neuroendocrine neoplasms (NENs) and 33% of patients with atypical bronchial carcinoid achieved an objective response. The median progression free survival was 4.8 months (95% CI 2.7, 10.5) and overall survival 14.8 months (95% CI 4.1,21.3). Immune-related toxicity was reported in 66% of patients with 34% experiencing grade 3/4 events. Conclusions Combination immunotherapy with ipilimumab and nivolumab demonstrated significant clinical activity